Curriculum: Personalised management of Prostate Cancer patients with history and risk of CVD events

This online curriculum addresses the unmet needs in personalised management of Prostate Cancer patients with history and risk of CVD events and is a mix of live webinars, case discussions, Q&A and discussions by key opinion leaders in prostate cancer. The programme is developed by The Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology.

The curriculum is divided in a series of educational online modules, each one consisting of pre-recorded sessions and a live webinar. Participants are recommended to watch the pre-recorded lectures as a preparation for the live webinar. Attending the live webinar is free (registration required) and participants joining live will receive accreditation points.

Coming up

Module 3: Advances in safety in the treatment of PCa

Pre-recorded lectures

• Dr. Alan So (CUA): Safety data – GNRH Analogues, focus on CVD risk profile
• Prof. Axel Merseburger (EAU): Safety data – mHSPC therapy and CVD risk profile

Live webinar

• 1 September 2021
• Ass. Prof. Katie Zhang (ICOS): Live case study (incl Cardiac biomarkers) + Q&A by panellists Dr. Alan So & Prof. Axel Merseburger

Module 4: Future directions in PCa management

Live webinar

• 16 November 2021
• Faculty: Neil Fleshner (CUA), Marc Garnick (EAU), Daniel Lenihan (ICOS)

On Demand

Module 2: Debate – How to manage CVD risk in PCa  patients during COVID 19

Live webinar

• Wednesday, 7 April 2021, 18:30 – 19:30 CET
• Faculty
  Moderator: Prof. P-A. Abrahamsson (SE)
  Presenter: Prof. A. Ghosh (GB) – “Impact of COVID-19 on cardio-oncology”
  Dr. M. Linch (GB) – “Hormonal treatment of urological cancers during COVID-19”
  Dr. R.A. Rendon (CA) – “How to manage prostate cancer in a pandemic”
  Prof. Dr. M.J. Ribal Caparros (ES) – “COVID-19 Recommendations for Prostate Cancer treatment by the EAU Guidelines”
  

Module 1: CVD in prostate cancer patients – Increased risks & comorbidities

Pre-recorded lectures

• Phil Cornford – EAU: The comorbidity burden in prostate cancer
  
• Darryl Leong – ICOS: Risk scoring of CVD in PCa patients undergoing hormonal PCa treatment
  

Live webinar

• Faculty: Laurence Klotz – CUA: Live Case discussion + Q&A by panellists Darryl Leong & Phil Cornford
  

This educational activity has been funded by Ferring Pharmaceuticals. The educational programme of this online activity has been a collaboration with Ferring, but independently developed and approved by the Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology.